Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Akcea Therapeutics Inc (AKCA)

Akcea Therapeutics Inc (AKCA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,846,054
  • Shares Outstanding, K 101,599
  • Annual Sales, $ 488,540 K
  • Annual Income, $ 40,770 K
  • 60-Month Beta 1.45
  • Price/Sales 3.77
  • Price/Cash Flow 35.60
  • Price/Book 3.85
Trade AKCA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.54
  • Most Recent Earnings -0.49 on 08/04/20
  • Next Earnings Date 11/03/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.34
  • Number of Estimates 2
  • High Estimate -0.26
  • Low Estimate -0.41
  • Prior Year -0.34
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.05 +0.66%
on 09/21/20
18.22 -0.27%
on 09/28/20
+0.03 (+0.17%)
since 09/09/20
3-Month
9.81 +85.22%
on 08/05/20
19.65 -7.53%
on 08/31/20
+4.88 (+36.72%)
since 07/09/20
52-Week
8.00 +127.13%
on 03/16/20
21.70 -16.29%
on 12/16/19
-1.57 (-7.95%)
since 10/09/19

Most Recent Stories

More News
WAYLIVRA(R) (volanesorsen), the First and Only Therapy for Familial Chylomicronaemia Syndrome, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in Scotland

Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the Scottish Medicines Consortium (SMC) has enabled access to volanesorsen on the National...

AKCA : 18.17 (+0.17%)
IONS : 37.21 (+2.14%)
Ionis and Akcea Recognize FCS Awareness Day With Global Community Efforts to Celebrate Unsung Heroes

Ionis Pharmaceuticals (NASDAQ: IONS) and its wholly owned subsidiary, Akcea Therapeutics, today recognize the 3rd annual Familial Chylomicronemia Syndrome (FCS) Awareness Day, a global observance held...

AKCA : 18.17 (+0.17%)
IONS : 37.21 (+2.14%)
Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)

CARLSBAD, Calif. and , /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary Akcea Therapeutics, Inc., today announced that Pfizer Inc. (NYSE: PFE) has initiated...

AKCA : 18.17 (+0.17%)
PFE : 43.89 (-1.30%)
IONS : 37.21 (+2.14%)
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product

and , /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary, Akcea Therapeutics, received the Prix Galien Award for the Best Biotechnology Product in 2020 in recognition...

AKCA : 18.17 (+0.17%)
IONS : 37.21 (+2.14%)
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics

, /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the successful completion of its transaction to acquire 100% ownership of Akcea Therapeutics, Inc. (NASDAQ: AKCA). The combination...

IONS : 37.21 (+2.14%)
AKCA : 18.17 (+0.17%)
Ionis' Alexander Disease Candidate Gets Orphan Drug Status

The FDA assigns an orphan drug designation to Ionis' (IONS) pipeline candidate ION373 for treating patients with Alexander disease.

BIIB : 300.19 (+0.17%)
RHHBY : 46.0700 (-1.60%)
IONS : 37.21 (+2.14%)
AKCA : 18.17 (+0.17%)
IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Investigations; Investors are Encouraged to Contact the Firm - AKCA, BLDR, DCOM, STND

, /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating:

AKCA : 18.17 (+0.17%)
BLDR : 52.82 (+0.04%)
DCOM : 31.17 (-1.39%)
STND : 33.00 (+0.06%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds AKCA, IMMU, and MXIM Shareholders About Its Ongoing Investigations

, /PRNewswire/ --

AKCA : 18.17 (+0.17%)
IMMU : 87.86 (+0.05%)
Lifshitz Law Firm, P.C. Announces Investigation of Akcea Therapeutics, Inc. (NASDAQ: AKCA), BMC Stock Holdings, Inc. (NASDAQ: BMCH), Builders FirstSource, Inc. (NASDAQ: BLDR), Cancer Genetics, Inc. (NASDAQ: CGIX), Cellular Biomedicine Group, Inc. (NASDAQ: CBMG), Otelco Inc. (NASDAQ: OTEL), Rosetta Stone Inc. (NYSE: RST), Varian Medical Systems, Inc. (NYSE: VAR), and Yintech Investment Holdings Limited (NASDAQ: YIN)

, /PRNewswire/ --

AKCA : 18.17 (+0.17%)
BMCH : 53.68 (-3.24%)
BLDR : 52.82 (+0.04%)
CGIX : 4.61 (-2.33%)
CBMG : 19.75 (unch)
OTEL : 11.74 (+0.15%)
RST : 29.99 (unch)
VAR : 177.07 (-0.02%)
YIN : 7.25 (+0.14%)
Moore Kuehn Encourages RST, AKCA, DCOM, and SBPH Investors to Contact Law Firm

, /PRNewswire/ -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown , is investigating potential claims concerning whether the following proposed mergers are fair...

RST : 29.99 (unch)
AKCA : 18.17 (+0.17%)
DCOM : 31.17 (-1.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Akcea Therapeutics, Inc. is a biopharmaceutical company. It focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The Company's drug pipeline consists of volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 18.20
1st Resistance Point 18.18
Last Price 18.17
1st Support Level 18.14
2nd Support Level 18.12
3rd Support Level N/A

See More

52-Week High 21.70
Last Price 18.17
Fibonacci 61.8% 16.47
Fibonacci 50% 14.85
Fibonacci 38.2% 13.24
52-Week Low 8.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar